Profile data is unavailable for this security.
About the company
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.
- Revenue in EUR (TTM)--
- Net income in EUR--
- Incorporated--
- Employees3.28k
- LocationDiaSorin SpAvia Crescentino sncSALUGGIA 13040ItalyITA
- Phone+39 161487526
- Fax+39 161487670
- Websitehttps://int.diasorin.com/en
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCHOTT Pharma AG & Co KgaA | 996.56m | 150.74m | 2.26bn | 4.81k | 14.94 | 2.43 | 9.44 | 2.26 | 1.00 | 1.00 | 6.63 | 6.18 | 0.6414 | 3.95 | 3.98 | 207,141.30 | 9.74 | 11.86 | 13.61 | 16.87 | 33.68 | 34.65 | 15.18 | 15.68 | 1.17 | -- | 0.0824 | 10.95 | 3.04 | 11.04 | -2.16 | 13.58 | 11.15 | -- |
| Asker Healthcare Group AB | 1.59bn | 46.46m | 2.35bn | 4.58k | 49.01 | -- | 18.77 | 1.48 | 1.33 | 1.33 | 45.59 | -- | 1.12 | 5.14 | 8.48 | 3,665,284.00 | 3.41 | -- | 4.52 | -- | 40.92 | -- | 3.04 | -- | 0.8497 | 3.20 | 0.4688 | -- | 11.73 | -- | 36.67 | -- | -- | -- |
| Carl Zeiss Meditec AG | 2.20bn | 120.62m | 2.40bn | 5.78k | 19.51 | -- | -- | 1.09 | 1.37 | 1.37 | 25.58 | -- | -- | -- | -- | 381,084.40 | -- | 8.00 | -- | 9.78 | 52.19 | 56.02 | 5.53 | 11.56 | -- | 7.38 | -- | 33.14 | 7.82 | 10.78 | -20.99 | 2.90 | 11.23 | 1.92 |
| Ambu A/S | 814.58m | 72.82m | 2.59bn | 5.43k | 40.31 | 3.64 | 20.98 | 3.18 | 2.04 | 2.04 | 22.85 | 22.64 | 0.8135 | 1.95 | 7.18 | 1,130,201.00 | 7.27 | 4.06 | 8.49 | 4.82 | 60.07 | 59.33 | 8.94 | 5.48 | 1.67 | 20.74 | 0.0845 | 21.23 | 11.98 | 11.10 | 159.15 | 20.37 | -2.24 | 7.17 |
| Amplifon SpA | 2.41bn | 115.62m | 3.12bn | 15.07k | 26.77 | 3.12 | 7.23 | 1.29 | 0.5144 | 0.5144 | 10.76 | 4.41 | 0.6234 | 20.42 | 10.46 | 159,803.00 | 3.00 | 4.21 | 4.36 | 5.78 | 22.49 | 61.07 | 4.81 | 7.16 | 0.5413 | 3.86 | 0.6612 | 41.46 | 6.60 | 6.82 | -6.29 | 5.99 | 9.95 | -- |
| Sectra AB | 211.28m | 61.04m | 3.12bn | 1.32k | 54.12 | 19.56 | 43.47 | 14.78 | 3.36 | 3.36 | 11.62 | 9.29 | 0.6688 | -- | 3.93 | 1,726,353.00 | 19.32 | 15.75 | 35.74 | 29.92 | 54.43 | 60.29 | 28.89 | 22.41 | -- | -- | 0.0505 | 19.27 | 19.85 | 4.47 | 31.51 | 18.87 | 7.19 | -- |
| Medacta Group SA | 645.78m | 94.89m | 3.25bn | 2.04k | 34.23 | 7.65 | 19.78 | 5.04 | 4.33 | 4.33 | 29.48 | 19.39 | 0.8113 | 0.853 | 5.83 | 308,527.50 | 11.92 | 9.07 | 15.29 | 11.84 | 67.55 | 69.31 | 14.69 | 11.57 | 0.9472 | 10.51 | 0.3751 | 18.68 | 15.62 | 13.71 | 53.89 | 43.79 | 15.22 | -- |
| Ottobock SE & Co KgaA | 1.64bn | 57.90m | 3.67bn | -- | 63.44 | 16.05 | 19.28 | 2.24 | 0.9048 | 0.9048 | 25.67 | 3.58 | -- | -- | -- | -- | -- | -- | -- | -- | 52.42 | -- | 3.42 | -- | 0.6458 | 3.18 | 0.8358 | -- | 7.33 | -- | -38.37 | -- | -- | -- |
| DiaSorin SpA | -100.00bn | -100.00bn | 4.14bn | 3.28k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.62 | -- | 9.57 | -- | 66.24 | -- | 19.69 | -- | -- | -- | 25.25 | 3.24 | 10.91 | 17.68 | 1.37 | 16.50 | 4.78 |
| Ypsomed Holding AG | 864.41m | 212.93m | 4.52bn | 2.00k | 21.22 | 5.10 | 15.05 | 5.23 | 14.21 | 14.21 | 57.70 | 59.14 | 0.6591 | 6.14 | 5.78 | 297,862.70 | 16.24 | 5.55 | 23.88 | 8.67 | 41.25 | 32.32 | 24.63 | 9.24 | 1.19 | 27.75 | 0.1199 | 19.78 | 36.54 | 13.69 | 11.66 | 49.46 | 18.48 | 61.54 |
| Getinge AB | 3.30bn | 213.23m | 4.83bn | 11.79k | 24.27 | 1.86 | 11.73 | 1.46 | 8.29 | 8.29 | 128.39 | 108.05 | 0.5808 | 2.91 | 5.36 | -- | 3.78 | 4.48 | 4.94 | 5.91 | 47.63 | 47.54 | 6.51 | 7.57 | 0.8595 | 7.05 | 0.2696 | 47.51 | 0.6042 | 3.24 | 37.85 | -6.96 | 4.69 | 9.63 |
| Demant A/S | 3.08bn | 317.00m | 5.04bn | 26.70k | 15.72 | 3.78 | -- | 1.64 | 11.21 | 7.31 | 108.71 | 46.67 | 0.6423 | 2.19 | 5.94 | 860,208.20 | 6.62 | 8.82 | 8.18 | 12.44 | 75.62 | 75.44 | 10.30 | 12.49 | 1.00 | 5.69 | 0.6791 | 0.00 | 2.46 | 9.69 | -18.09 | 16.13 | 5.16 | -- |
| ConvaTec Group PLC | 1.99bn | 182.60m | 5.11bn | 10.48k | 29.42 | 3.51 | 13.83 | 2.57 | 0.0773 | 0.0773 | 0.84 | 0.6474 | 0.637 | 2.74 | 6.31 | 164,651.80 | 5.86 | 3.35 | 6.63 | 3.91 | 55.90 | 55.73 | 9.20 | 5.88 | 1.15 | 4.78 | 0.4252 | 94.67 | 6.85 | 4.61 | 46.20 | 81.02 | 14.74 | 1.20 |
Data as of Feb 13 2026. Currency figures normalised to DiaSorin SpA's reporting currency: Euro EUR
10.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price International Ltd.as of 28 Apr 2025 | 1.70m | 3.03% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 855.82k | 1.53% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 672.26k | 1.20% |
| Financi�re de l'�chiquier SAas of 30 Sep 2025 | 643.65k | 1.15% |
| CCLA Investment Management Ltd.as of 30 Jun 2025 | 642.95k | 1.15% |
| Goldman Sachs Asset Management LPas of 06 Feb 2026 | 368.92k | 0.66% |
| Wellington Management International Ltd.as of 30 Jan 2026 | 343.10k | 0.61% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 331.60k | 0.59% |
| Grandeur Peak Global Advisors LLCas of 31 Oct 2025 | 248.24k | 0.44% |
| Shareholder Value Management AGas of 30 Jan 2026 | 223.93k | 0.40% |
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
